Delivery of Therapeutic Proteins via Extracellular Vesicles: Review and Potential Treatments for Parkinson’s Disease, Glioma, and Schwannoma

被引：0
作者：
Justin Hall
Shilpa Prabhakar
Leonora Balaj
Charles P. Lai
Richard A. Cerione
Xandra O. Breakefield
机构：
[1] Cornell University,Departments of Chemistry and Chemical Biology and Molecular Medicine
[2] Harvard Medical School,Department of Neurology and Center for Molecular Imaging Research, Department of Radiology, Massachusetts General Hospital and NeuroDiscovery Center
[3] National Tsing Hua University,Institute of Biomedical Engineering
[4] Massachusetts General Hospital-East,Molecular Neurogenetics Unit
来源：
Cellular and Molecular Neurobiology | 2016年 / 36卷
关键词：
Exosomes; Extracellular vesicles; Parkinson’s disease; Glioma; Schwannoma; Therapeutic protein delivery;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Extracellular vesicles present an attractive delivery vehicle for therapeutic proteins. They intrinsically contain many proteins which can provide information to other cells. Advantages include reduced immune reactivity, especially if derived from the same host, stability in biologic fluids, and ability to target uptake. Those from mesenchymal stem cells appear to be intrinsically therapeutic, while those from cancer cells promote tumor progression. Therapeutic proteins can be loaded into vesicles by overexpression in the donor cell, with oligomerization and membrane sequences increasing their loading. Examples of protein delivery for therapeutic benefit in pre-clinical models include delivery of: catalase for Parkinson’s disease to reduce oxidative stress and thus help neurons to survive; prodrug activating enzymes which can convert a prodrug which crosses the blood–brain barrier into a toxic chemotherapeutic drug for schwannomas and gliomas; and the apoptosis-inducing enzyme, caspase-1 under a Schwann cell specific promoter for schwannoma. This therapeutic delivery strategy is novel and being explored for a number of diseases.
引用
收藏
页码：417 / 427
页数：10
相关论文
共 625 条
[1]  
Abraham S(2005)Erythrocyte antioxidant enzymes in Parkinson’s disease Indian J Med Res 121 111-115
[2]  
Soundararajan CC(2008)Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells Nat Cell Biol 10 619-624
[3]  
Vivekanandhan S(2011)Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes Nat Biotechnol 29 341-345
[4]  
Behari M(2001)Dynamics of intracellular granules with CD63-GFP in rat basophilic leukemia cells J Biochem 129 739-744
[5]  
Al-Nedawi K(1975)Brain peroxidase and catalase in Parkinson disease Arch Neurol 32 114-118
[6]  
Meehan B(2011)Cancer cell-derived microvesicles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells Proc Natl Acad Sci U S A 108 4852-4857
[7]  
Micallef J(1970)Studies on the chemotherapy of experimental brain tumors: development of an experimental model Cancer Res 30 2394-2400
[8]  
Lhotak V(1995)Apoptosis and increased generation of reactive oxygen species in Down’s syndrome neurons in vitro Nature 378 776-779
[9]  
May L(2011)Exosomes: immune properties and potential clinical implementations Semin Immunopathol 33 419-440
[10]  
Guha A(2013)Exosomes carrying mycobacterial antigens can protect mice against Eur J Immunol 43 3279-3290
12345678910